OptimiTM-03.jpg
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
September 14, 2023 14:59 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
OptimiTM-03.jpg
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
September 07, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly...
OptimiTM-03.jpg
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
September 05, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
headshots-jj-wilson-optimi-3
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
August 10, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada...
OptimiTM-03.jpg
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
August 01, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Announces Receipt of Purported Termination Notice
July 27, 2023 09:20 ET | Optimi Health Corp.
VANCOUVER, British Columbia, July 27, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for...
OptimiTM-03.jpg
Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
June 15, 2023 09:40 ET | Optimi Health Corp.
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
May 17, 2023 08:15 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Granted Natural Health Product Site Licence By Health Canada
May 10, 2023 08:45 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
May 04, 2023 09:00 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...